The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDestiny Pharma. Share News (DEST)

Share Price Information for Destiny Pharma. (DEST)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 17.00
Bid: 16.50
Ask: 17.50
Change: -0.50 (-2.86%)
Spread: 1.00 (6.061%)
Open: 17.50
High: 17.50
Low: 17.00
Prev. Close: 17.50
DEST Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Ecofin US Renewables expects to pay reduced dividend

Thu, 29th Jun 2023 18:55

(Alliance News) - The following is a round-up of updates by London-listed companies, issued Thursday and not separately reported by Alliance News:

----------

Serica Energy PLC - London-based oil & gas company focused on the UK North Sea - Provides update at annual general meeting. Says net production for the combined Serica and Tailwind portfolios has averaged over 49,000 barrels of oil equivalent per day in the year to June 24. Full year 2023 production guidance remains unchanged at 40,000-47,000 boe/d. Production costs for the group are running at around USD17/boe year-to-date in line with expectations.

----------

Destiny Pharma PLC - Brighton, England-based clinical-stage biotechnology company focused on preventing life-threatening infections - Updates on the progress made on business development and partnering activities relating to XF-73 Nasal, its lead asset. Says active discussions are progressing at various stages with a number of interested global parties having access to the XF-73 data room, and the company anticipates several more potential partners will be granted access in the coming months. Further, says search for permanent chief executive officer continues.

----------

Physiomics PLC - London-based mathematical modelling company that supports oncology drug development - Completes subscription, retail offer and placing to raise total GBP380,477, announced on June 27. Further, places extra 2 million shares to raise GBP345,000. Proceeds to be used for further expansion and diversification of its client base, expansion of its consulting business and exploration of opportunities around its personalised oncology software offering.

----------

Ceres Power Holdings PLC - clean energy technology developer - Shares cancelled for trading on AIM on Thursday and admitted to listing on the premium listing segment of the Official List.

----------

Faron Pharmaceuticals Oy - Finland-based clinical-stage biopharmaceutical company - Conducts private placement to a limited number of institutional and other investors to raise EUR 6.6 million. Significant majority of the net proceeds will be used for the acceleration of the bexmarilimab clinical development program and manufacturing. Explains proceeds of the placing, together with other currently confirmed funding, are expected to provide the company with working capital into the fourth quarter of 2023.

----------

Jadestone Energy PLC - oil and gas production company focused on Asia-Pacific region - Reports acceptances of only 0.5% of eligible shareholders for open offer announced earlier in June. Notes the company's share price was below the open offer price of 45 pence per share for the duration of the open offer, which is likely to explain the level of applications. Open offer will thus raise USD33,101.

----------

Ecofin US Renewables Infrastructure Trust - London-based investor in US renewable energy assets - Expects net cash flows at the portfolio level to be meaningfully lower than forecast for the quarters ending June 30 and September 30, with overall cash flows currently expected to return to forecast levels by the end of the calendar year. Says this reduction comes as a result of certain operational issues, including the recent events at Whirlwind, corrective maintenance interruptions at some of the solar assets leading to lower-than-expected energy performance, and one-time costs. As a result, expects to declare a reduced dividend of not less than 0.70 US cents per share in respect of the quarter ending June 30. Believes a temporary reduction at this time is prudent. It had paid a first-quarter dividend of 1.4 US cents per share.

----------

By Jeremy Cutler, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
15 Nov 2021 20:37

IN BRIEF: Destiny Pharma's Morgan to step down from board in March

IN BRIEF: Destiny Pharma's Morgan to step down from board in March

Read more
18 Oct 2021 15:12

TRADING UPDATES: Mind Gym revenue recovers; Dispersion buys Accru

TRADING UPDATES: Mind Gym revenue recovers; Dispersion buys Accru

Read more
18 Oct 2021 09:25

Destiny Pharma upbeat on recent study into mupirocin alternative

(Sharecast News) - Clinical-stage biotechnology company Destiny Pharma said on Monday that a major US hospital-based clinical trial lent "strong support" for the potential of its 'XF-73' nasal product as an alternative to mupirocin in the treatment of Staphylococcus aureus infections.

Read more
27 Sep 2021 10:58

IN BRIEF: Destiny Pharma unveils new XF-73 skin infection drug project

IN BRIEF: Destiny Pharma unveils new XF-73 skin infection drug project

Read more
27 Sep 2021 10:10

Destiny Pharma's China partner starts new XF-73 programme

(Sharecast News) - Clinical-stage biotechnology company Destiny Pharma announced on Monday that its China regional partner and investor, China Medical System Holdings (CMS), is establishing a new programme with 'XF-73' targeting the prevention and treatment of superficial skin infections caused by bacteria.

Read more
9 Sep 2021 11:33

EARNINGS UPDATES: STV, Chaarat, Sportech, Bacanora enter black

EARNINGS UPDATES: STV, Chaarat, Sportech, Bacanora enter black

Read more
2 Sep 2021 14:55

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
2 Aug 2021 11:39

TRADING UPDATES: Brickability buys Leadcraft; Aquis has record July

TRADING UPDATES: Brickability buys Leadcraft; Aquis has record July

Read more
2 Aug 2021 11:34

Destiny Pharma reports positive secondary data on 'XF-73'

(Sharecast News) - Clinical-stage biotechnology company Destiny Pharma announced additional, "strong" data from its recent phase 2b clinical trial on Monday.

Read more
6 Jul 2021 20:38

TRADING UPDATES: Hipgnosis placing oversubscribed; Creightons delays

TRADING UPDATES: Hipgnosis placing oversubscribed; Creightons delays

Read more
6 Jul 2021 10:35

Destiny Pharma inks research deal with US Veterans' Affairs

(Sharecast News) - Clinical-stage biotechnology company Destiny Pharma announced a cooperative research and development agreement with the US Department of Veterans' Affairs on Tuesday, to support studies focusing on identifying new attributes for 'NTCD-M3' - a novel microbiome therapeutic being developed to reduce the recurrence of Clostridioides difficile infections in the gut.

Read more
10 Jun 2021 19:46

TRADING UPDATES: Ergomed and Dekel Agri-Vision earnings growing

TRADING UPDATES: Ergomed and Dekel Agri-Vision earnings growing

Read more
7 Jun 2021 17:59

TRADING UPDATES: Alba Mineral in Thule asset boost; Nuformix US patent

TRADING UPDATES: Alba Mineral in Thule asset boost; Nuformix US patent

Read more
2 Jun 2021 19:10

TRADING UPDATES: Block Energy 2020 revenue jumps; Kanabo loss narrows

TRADING UPDATES: Block Energy 2020 revenue jumps; Kanabo loss narrows

Read more
2 Jun 2021 10:26

Destiny Pharma reports positive progress on lead clinical programme

(Sharecast News) - Clinical stage biotechnology company Destiny Pharma announced positive progress with its lead clinical programme, 'NTCD-M3', on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.